Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bfbe7e8dbb43a34abff046accf945c9d7> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bfbe7e8dbb43a34abff046accf945c9d7 NCIT_P378 "NCI" @default.
- Bfbe7e8dbb43a34abff046accf945c9d7 type Axiom @default.
- Bfbe7e8dbb43a34abff046accf945c9d7 annotatedProperty IAO_0000115 @default.
- Bfbe7e8dbb43a34abff046accf945c9d7 annotatedSource NCIT_C182002 @default.
- Bfbe7e8dbb43a34abff046accf945c9d7 annotatedTarget "A preparation of human T-lymphocytes genetically engineered to express an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) gene and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of transforming growth factor-beta receptor II (TGFbRII), with potential immunostimulatory and antineoplastic activities. Upon administration, the CRISPR-Cas9 engineered TGFbRII-deleted anti-EGFR CAR T-cells target and bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. By knocking out the expression of TGFbRII, the immunosuppressive cytokine TGF-beta is unable to bind to the T-cells and prevent the activation of the T-cells. TGF-beta contributes to the immunosuppressive nature of the tumor microenvironment (TME), and plays a key role in promoting tumor initiation, metastasis, and suppressing anti-tumor immunity." @default.